Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: A potential therapeutic target

Oncogene

Volumn 36, Issue 2, 2017, Pages 168-181

  Saini, U ^a   Naidu, S ^a   Elnaggar, A C ^a   Bid, H K ^a   Wallbillich, J J ^a   Bixel, K ^a   Bolyard, C ^b   Suarez, A A ^a   Kaur, B ^b   Kuppusamy, P ^c   Hays, J ^a   Goodfellow, P J ^a   Cohn, D E ^a   Selvendiran, K ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA ACTIN; CISPLATIN; CYCLIN D1; CYCLIN D2; CYTOKERATIN; DOXORUBICIN; GELATINASE A; GELATINASE B; HO 3867; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; PROTEIN INHIBITOR; PROTEIN KINASE B; SHORT HAIRPIN RNA; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; SURVIVIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; (3,5-BIS((4-FLUOROPHENYL)METHYLIDENE)-1-((1-HYDROXY-2,2,5,5-TETRAMETHYL-2,5-DIHYDRO-1H-PYRROL-3-YL)METHYL)PIPERIDIN-4-ONE); PIPERIDONE DERIVATIVE; STAT3 PROTEIN, HUMAN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES CELL LINE; ASCITES DERIVED OVARIAN CANCER CELL; CANCER GRAFT; CANCER INHIBITION; CANCER RESISTANCE; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; DRUG EFFICACY; DRUG TARGETING; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LIVER METASTASIS; MALIGNANT ASCITES; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CANCER; PERITONEUM METASTASIS; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TISSUE CULTURE TECHNIQUE; TUMOR GROWTH; TUMOR INVASION; ANIMAL; ASCITES; CELL MOTION; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENETICS; METABOLISM; METASTASIS; OVARIAN NEOPLASMS; PATHOLOGY; UPREGULATION;

ANIMALS; ASCITES; CELL MOVEMENT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKOUT TECHNIQUES; HUMANS; MICE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; PIPERIDONES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84974733308     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2016.197     Document Type: Article

References (49)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29
2. Coleman RL, Monk BJ, Sood AK, Herzog TJ. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol 2013; 10: 211-224
3. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol 2010; 177: 1053-1064
4. Naora H, Montell DJ. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer 2005; 5: 355-366
5. Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P, Miyake T et al. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell 2014; 26: 77-91
6. Ahmed N, Stenvers KL. Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Front Oncol 2013; 3: 256
7. Kipps E, Tan DS, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer 2013; 13: 273-282
8. Latifi A, Luwor RB, Bilandzic M, Nazaretian S, Stenvers K, Pyman J et al. Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. PloS One 2012; 7: e46858
9. Selvendiran K, Bratasz A, Kuppusamy ML, Tazi MF, Rivera BK, Kuppusamy P. Hypoxia induces chemoresistance in ovarian cancer cells by activation of signal transducer and activator of transcription 3. Int J Cancer 2009; 125: 2198-2204
10. Pradeep S, Huang J, Mora EM, Nick AM, Cho MS, Wu SY et al. Erythropoietin stimulates tumor growth via EphB4. Cancer Cell 2015; 28: 610-622
11. Selvendiran K, Tong L, Bratasz A, Kuppusamy ML, Ahmed S, Ravi Y et al. Anticancer efficacy of a difluorodiarylidenyl piperidone (HO-3867) in human ovarian cancer cells and tumor xenografts. Mol Cancer Ther 2010; 9: 1169-1179
12. Selvendiran K, Ahmed S, Dayton A, Ravi Y, Kuppusamy ML, Bratasz A et al. HO-3867, a synthetic compound, inhibits the migration and invasion of ovarian carcinoma cells through downregulation of fatty acid synthase and focal adhesion kinase. Mol Cancer Res 2010; 8: 1188-1197
13. Tierney BJ, McCann GA, Naidu S, Rath KS, Saini U, Wanner R et al. Aberrantly activated pSTAT3-Ser727 in human endometrial cancer is suppressed by HO-3867, a novel STAT3 inhibitor. Gynecol Oncol 2014; 135: 133-141
14. Rath KS, Naidu SK, Lata P, Bid HK, Rivera BK, McCann GA et al. HO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancer. Cancer Res 2014; 74: 2316-2327
15. Kalai T, Kuppusamy ML, Balog M, Selvendiran K, Rivera BK, Kuppusamy P et al. Synthesis of N-substituted 3, 5-bis(arylidene)-4-piperidones with high antitumor and antioxidant activity. J Med Chem 2011; 54: 5414-5421
16. Tierney BJ, McCann GA, Cohn DE, Eisenhauer E, Sudhakar M, Kuppusamy P et al. HO-3867, a STAT3 inhibitor induces apoptosis by inactivation of STAT3 activity in BRCA1-mutated ovarian cancer cells. Cancer Biol Ther 2012; 13: 766-775
17. Kim D, Lee IH, Kim S, Choi M, Kim H, Ahn S et al. A specific STAT3-binding peptide exerts antiproliferative effects and antitumor activity by inhibiting STAT3 phosphorylation and signaling. Cancer Res 2014; 74: 2144-2151
18. Kroon P, Berry PA, Stower MJ, Rodrigues G, Mann VM, Simms M et al. JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells. Cancer Res 2013; 73: 5288-5298
19. Zhang X, Yue P, Page BD, Li T, Zhao W, Namanja AT et al. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci USA 2012; 109: 9623-9628
20. Mace TA, Ameen Z, Collins A, Wojcik S, Mair M, Young GS et al. Pancreatic cancerassociated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Cancer Res 2013; 73: 3007-3018
21. Selvendiran K, Koga H, Ueno T, Yoshida T, Maeyama M, Torimura T et al. Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: an implication for the antitumor potential of flavonoids. Cancer Res 2006; 66: 4826-4834
22. Huang F, Tong X, Fu L, Zhang R. Knockdown of STAT3 by shRNA inhibits the growth of CAOV3 ovarian cancer cell line in vitro and in vivo. Acta Biochim Biophys Sin (Shanghai) 2008; 40: 519-525
23. Dayton A, Selvendiran K, Kuppusamy ML, Rivera BK, Meduru S, Kalai T et al. Cellular uptake, retention and bioabsorption of HO-3867, a fluorinated curcumin analog with potential antitumor properties. Cancer Biol Ther 2010; 10: 1027-1032
24. Goff B. Measuring ovarian cancer care: why are we still failing?. Gynecol Oncol 2015; 136: 1-2
25. Matte I, Lane D, Bachvarov D, Rancourt C, Piche A. Role of malignant ascites on human mesothelial cells and their gene expression profiles. BMC Cancer 2014; 14: 288
26. Seo JM, Park S, Kim JH. Leukotriene B4 receptor-2 promotes invasiveness and metastasis of ovarian cancer cells through signal transducer and activator of transcription 3 (STAT3)-dependent up-regulation of matrix metalloproteinase 2. J Biol Chem 2012; 287: 13840-13849
27. Gritsina G, Xiao F, O'Brien SW, Gabbasov R, Maglaty MA, Xu RH et al. Targeted blockade of JAK/STAT3 signaling inhibits ovarian carcinoma growth. Mol Cancer Ther 2015; 14: 1035-1047
28. Chiarle R, Simmons WJ, Cai H, Dhall G, Zamo A, Raz R et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 2005; 11: 623-629
29. Pedranzini L, Leitch A, Bromberg J. Stat3 is required for the development of skin cancer. J Clin Invest 2004; 114: 619-622
30. Lee MY, Joung YH, Lim EJ, Park JH, Ye SK, Park T et al. Phosphorylation and activation of STAT proteins by hypoxia in breast cancer cells. Breast 2006; 15: 187-195
31. Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer 2014; 14: 736-746
32. Putoczki T, Ernst M. More than a sidekick: the IL-6 family cytokine IL-11 links inflammation to cancer. J Leukoc Biol 2010; 88: 1109-1117
33. Ernst M, Najdovska M, Grail D, Lundgren-May T, Buchert M, Tye H et al. STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J Clin Invest 2008; 118: 1727-1738
34. Lee H, Deng J, Kujawski M, Yang C, Liu Y, Herrmann A et al. STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat Med 2010; 16: 1421-1428
35. McCann GA, Naidu S, Rath KS, Bid HK, Tierney BJ, Suarez A et al. Targeting constitutively-activated STAT3 in hypoxic ovarian cancer, using a novel STAT3 inhibitor. Oncoscience 2014; 1: 216-228
36. Darnell JE. Validating Stat3 in cancer therapy. Nat Med 2005; 11: 595-596
37. Venkatesh S, Lipper RA. Role of the development scientist in compound lead selection and optimization. J Pharm Sci 2000; 89: 145-154
38. Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, Lawrence HR et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci USA 2007; 104: 7391-7396
39. Wen W, Liang W, Wu J, Kowolik CM, Buettner R, Scuto A et al. Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer. Mol Cancer Ther 2014; 13: 3037-3048
40. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005; 11: 1314-1321
41. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm 2007; 4: 807-818
42. Cheng X, Rasque P, Vatter S, Merz KH, Eisenbrand G. Synthesis and cytotoxicity of novel indirubin-5-carboxamides. Bioorg Med Chem 2010; 18: 4509-4515
43. Hsu HS, Huang PI, Chang YL, Tzao C, Chen YW, Shih HC et al. Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells. Cancer 2011; 117: 2970-2985
44. Bill MA, Fuchs JR, Li C, Yui J, Bakan C, Benson DM Jr. et al. The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-Tumor activity. Mol Cancer 2010; 9: 165
45. Greten FR, Karin M. Peering into the aftermath: JAKi rips STAT3 in cancer. Nat Med 2010; 16: 1085-1087
46. Vaira V, Fedele G, Pyne S, Fasoli E, Zadra G, Bailey D et al. Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc Natl Acad Sci USA 2010; 107: 8352-8356
47. Bolyard C, Yoo JY, Wang PY, Saini U, Rath KS, Cripe TP et al. Doxorubicin synergizes with 34.5ENVE to enhance antitumor efficacy against metastatic ovarian cancer. Clin Cancer Res 2014; 20: 6479-6494
48. Yoo JY, Hurwitz BS, Bolyard C, Yu JG, Zhang J, Selvendiran K et al. Bortezomibinduced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects. Clin Cancer Res 2014; 20: 3787-3798
49. Pirnia F, Frese S, Gloor B, Hotz MA, Luethi A, Gugger M et al. Ex vivo assessment of chemotherapy-induced apoptosis and associated molecular changes in patient tumor samples. Anticancer Res 2006; 26: 1765-1772